- Report
- September 2026
- 180 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 376 Pages
Global
From €5316EUR$5,850USD£4,569GBP
- Report
- January 2026
- 180 Pages
Global
From €4089EUR$4,500USD£3,515GBP
- Report
- March 2026
- 149 Pages
Global
From €2725EUR$2,999USD£2,343GBP
€3634EUR$3,999USD£3,124GBP
- Report
- December 2025
- 150 Pages
Global
From €4407EUR$4,850USD£3,788GBP
- Report
- August 2026
- 160 Pages
Global
From €3017EUR$3,320USD£2,593GBP
€3771EUR$4,150USD£3,242GBP
- Report
- August 2026
- 160 Pages
Global
From €3017EUR$3,320USD£2,593GBP
€3771EUR$4,150USD£3,242GBP
- Report
- September 2026
- 191 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- February 2026
- 144 Pages
Global
From €3589EUR$3,950USD£3,085GBP
- Report
- August 2026
- 160 Pages
Global
From €3017EUR$3,320USD£2,593GBP
€3771EUR$4,150USD£3,242GBP
- Report
- June 2026
- 200 Pages
Global
From €2717EUR$2,990USD£2,335GBP
- Report
- April 2026
- 200 Pages
Global
From €2717EUR$2,990USD£2,335GBP
- Report
- September 2026
- 191 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 184 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 194 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 185 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- January 2026
- 184 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 189 Pages
Global
From €5316EUR$5,850USD£4,569GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP

The Human Insulin market is a segment of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Human Insulin is a synthetic form of insulin, which is produced in a laboratory and is identical to the insulin produced by the human body. It is used to treat both type 1 and type 2 diabetes. Human Insulin is available in a variety of forms, including short-acting, intermediate-acting, and long-acting. It is typically administered via injection or an insulin pump.
Some companies in the Human Insulin market include Novo Nordisk, Sanofi, Eli Lilly, and Biocon. Show Less Read more